The Lung Cancer SPORE Biostatistics and Informatics Core provides support in the areas of biostatistics, clinical informatics, and bioinformatics to SPORE investigators. This consultative and collaborative support is designed to increase the speed and efficiency with which lung cancer research is translated from the lab to the clinic. The Core is designed to provide support in study design, data management, data analysis, clinical informatics system creation, bioinformatics data management and interpretation. The Biostatistics group assists primarily with study and protocol design, and data analysis and interpretation. The Informatics group assists with data quality control, data sharing, designing and maintaining the SPORE database that captures clinical, pathologic, and laboratory data into a relational database. This group also designed the barcode system for collection and storage of all samples. The Bioinformatics group assists with computational evaluations of large databases, especially those created with genomic and proteomic analysis using gene expression and SNP arrays and proteomic profiles. All Core members participate in preparation of reports, presentations, and manuscripts. In addition to these services, Core members will continue their efforts to develop new approaches to improve the efficiency and outcomes of the process of translational research. Biostatistics and Informatics Core members will assist SPORE investigators in the following areas: 1. Experimental design. Design of both pre-clinical and clinical experiments that can provide useful answers to scientific questions of importance in lung cancer. 2. Data collection/storage/retrieval/sharing: Creation and maintenance of a sound and user-friendly infrastructure for data collection, storage, quality assurance, retrieval, and sharing in support of SPORE trials and tissue banking. 3. Data analysis and manuscript preparation: Structuring of data analyses to provide clear answers to questions, and to communicate those findings in reports and papers. 4. Translational research methodology: Development and implementation of coherent methods that improve the efficiency and effectiveness of research across the wide spectrum from pre-clinical research to clinical studies, including work in the development of better understanding of the causes of lung cancer, early detection of lung cancer, biomarkers of lung cancer risk, and lung cancer therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058187-18
Application #
8376667
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
18
Fiscal Year
2012
Total Cost
$249,607
Indirect Cost
$73,474
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739
Pilling, Amanda B; Kim, Jihye; Estrada-Bernal, Adriana et al. (2018) ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget 9:8823-8835
Kwak, Jeff W; Laskowski, Jennifer; Li, Howard Y et al. (2018) Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Res 78:143-156
Sakamoto, Mandy R; Honce, Justin M; Lindquist, Deborah L et al. (2018) Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Clin Lung Cancer :
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Geraci, Mark W (2018) TARGETING THE PROSTACYCLIN/PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AXIS IN LUNG CANCER CHEMOPREVENTION. Trans Am Clin Climatol Assoc 129:48-55
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Kimball, Abigail K; Oko, Lauren M; Bullock, Bonnie L et al. (2018) A Beginner's Guide to Analyzing and Visualizing Mass Cytometry Data. J Immunol 200:3-22
Tippimanchai, Darinee D; Nolan, Kyle; Poczobutt, Joanna et al. (2018) Adenoviral vectors transduce alveolar macrophages in lung cancer models. Oncoimmunology 7:e1438105

Showing the most recent 10 out of 435 publications